Show simple item record

dc.creatorSaghazadeh, Amene
dc.creatorRezaei, Nima
dc.date.accessioned2020-07-10T17:55:29Z
dc.date.available2020-07-10T17:55:29Z
dc.date.created2020
dc.identifier.issn1567-5769spa
dc.identifier.otherhttps://doi.org/10.1016/j.intimp.2020.106560spa
dc.identifier.urihttp://hdl.handle.net/20.500.12010/10407
dc.description.abstractThe novel coronavirus, SARS-CoV2, can cause a potentially fatal disease, COVID-19, in humans. Here, we will provide an overview of therapeutic options for COVID-19. Plasma from patients recovered from COVID-19 that contains antibodies against SARS-CoV2 has shown promising results in patients with severe COVID-19. Also, IVIG, combined with moderate-dose of corticosteroids, might improve patient outcomes. Evidence links COVID19 to variable degrees of inflammation. Studies show that the use of corticosteroids might accelerate recovery from COVID-19. There are, however, no controlled clinical trials that show whether the use of corticosteroids can reduce COVID-19-related death. Also, the pro-inflammatory cytokine IL6 is the best-documented cytokine in COVID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels. Essential elements that process SARS-CoV2 cell entry and specific characteristics that allow SARS-CoV2 to escape the immune system have the potential as targets for COVID-19 therapy.spa
dc.format.extent6 páginasspa
dc.format.mimetypeimage/jepgspa
dc.publisherScience Directeng
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectCOVID-19spa
dc.subjectTreatmentspa
dc.subjectImmunoglobulinspa
dc.subjectTargeted therapyspa
dc.subjectCorticosteroidsspa
dc.subjectInterleukin 6spa
dc.titleTowards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, and corticosteroidsspa
dc.type.localArtículospa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.identifier.doihttps://doi.org/10.1016/j.intimp.2020.106560spa


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record